诱导多能干细胞
视网膜
视网膜
视网膜色素上皮
胶质增生
视网膜变性
细胞生物学
黄斑变性
移植
生物
胚胎干细胞
医学
解剖
眼科
神经科学
外科
遗传学
基因
作者
Anna Brýmová,Francisco Javier Rodríguez-Jiménez,Annika C. Konrad,Yaroslav Nemesh,Muhammed Arshad Thottappali,Ana Artero‐Castro,Ruslan Nyshchuk,A. F. Kolesnikova,Brigitte Müller,Hana Studenovská,Jana Juhasová,Štefan Juhás,Ivona Valeková,Dunja Lukovic,Claudia Aleman,Taras Ardan,Saskia Drutovič,Jan Motlík,Zdeňka Ellederová,Zbyněk Straňák
标识
DOI:10.1002/advs.202412301
摘要
In late stages of inherited and acquired retinal diseases such as Stargardt disease (STGD) or dry age-related macular degeneration (AMD), loss of retinal pigment epithelia (RPE) cells and subsequently photoreceptors in the macular area result in a dramatic decline of central visual function. Repopulating this area with functional RPE cells may prevent or decline the progression of photoreceptor loss. In the present study, the viability, survival, and integration of human induced pluripotent stem cell (hiPSC)-derived RPE cells (hiPSC-RPE) is assessed generated using clinical-grade protocol and cultured on a clinically relevant scaffold (poly-L-lactide-co-D, L-lactide, PDLLA) after subretinal implantation in immunosuppressed minipigs for up to 6 weeks. It is shown that transplanted hiPSC-RPE cells maintain the RPE cell features such as cell polarity, hexagonal shape, and cell-cell contacts, and interact closely with photoreceptor outer segments without signs of gliosis or neuroinflammation throughout the entire period of examination. In addition, an efficient immunosuppressing strategy with a continuous supply of tacrolimus is applied. Continuous verification and improvement of existing protocols are crucial for its translation to the clinic. The results support the use of hiPSC-RPE on PDLLA scaffold as a cell replacement therapeutic approach for RPE degenerative diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI